Friday, May 23, 2025 | 05:53 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Medicines, Pharma
Premium

25 per cent of the Indian drug market is under price control, for the rest, firms can take a 10 per cent hike annually in prices

Sohini Das Mumbai
The share of the Indian market in the overall turnover of pharmaceutical (pharma) companies has risen in the past few years. There are several reasons behind this: pricing pressure in the US generics market, currency volatility in the emerging markets (EMs), and India being the only consistent geography with stable prices and demand.

A Business Standard analysis reveals how the share of the India business in the overall turnover rose steadily from 25 per cent in 2018-19 (FY19) for Sun Pharmaceutical Industries (Sun Pharma) to 33 per cent in 2021-22 (FY22). The company ranks No. 1 in the Indian market,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in